126 filings
8-K
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
28 Mar 24
Termination of a Material Definitive Agreement
4:05pm
8-K
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
QLGN
Qualigen Therapeutics Inc
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
7 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
4ymjc
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
0jiz8 w21
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
8-K
64q uxa76a
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
8-K
wfkjidlzor2m 07
17 Oct 23
Regulation FD Disclosure
8:30am
8-K
qoxi18
28 Sep 23
Entry into a Material Definitive Agreement
4:15pm
8-K
6nli43uk
15 Aug 23
Results of Operations and Financial Condition
10:04am
8-K
hspak2c6t pd8k32h74p
4 Aug 23
Departure of Directors or Certain Officers
4:30pm
8-K
2y12 dbyx
1 Aug 23
Regulation FD Disclosure
8:35am
8-K
vrbqv92h5
26 Jul 23
Entry into a Material Definitive Agreement
5:25pm
8-K
kbh57
13 Jul 23
Submission of Matters to a Vote of Security Holders
5:29pm
8-K
z6fuq88s k9q2ip3h3ai
26 Jun 23
Departure of Directors or Certain Officers
5:25pm
8-K
e4zx1bz
19 May 23
Departure of Directors or Certain Officers
8:20am
8-K
ea5gkpbbpliv3dqi qrv
5 May 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:15pm
8-K
sczo16mp 2pjbs7dpdy
24 Apr 23
Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing
6:15am
8-K
adqc9bn5gnabcmufth9p
13 Feb 23
Regulation FD Disclosure
9:30am